We are excited to make semaglutide/GLP-1 treatment available to all Legacy providers. This is a new direction for Portrait and for providers, and so it’s important that we are optimally aligned.
In most states, we are working with a single compounding pharmacy. California Board of Pharmacy doesn’t allow semaglutide to be compounded nor do they allow pharmacies permitted to ship it into California. We have procured the actual synthetic GLP-1 peptide for use in California.
Operational flow:
In CA, inventory will come from headquarters due to large order minimums. Shipping costs are exorbitant ($100-$150 to the hub and then cold chain to your office) and so in order to make this tenable, providers need to cover a small portion of the shipping cost (approximately $20-$25).
In order to make sure that we are fully aligned on the process for dispensing GLP-1 agonists including semaglutide from your suites, we need you to review and acknowledge below.
1) I will carefully review and follow the Help Desk guidelines regarding appropriate marketing (avoid making unsubstantiated claims, avoid brand name usage).
2) I understand that Portrait needs to maintain an inventory budget and GLP-1/semaglutide counts against my inventory budget. I understand Portrait will no longer be accepting inventory return from providers and will consider that when placing my order.
3) I understand that receiving and appropriately storing and securing inventory is my responsibility.
4) I understand that appropriate documentation is absolutely required. Numerous patients have been hospitalized with gastroparesis and hypoglycemia from these peptides. For RN providers, I understand that I must communicate with the GFE provider if my patient is experiencing significant side effects during any point they are on semaglutide.
5) I will not have unlicensed personnel or anyone other than me administer semaglutide unless I have received written permission from the Chief Medical Officer, as in many situations this would violate the law and my contract.
